233 related articles for article (PubMed ID: 29297899)
1. [Combination strategies in melanoma therapy.].
Spagnolo F
Recenti Prog Med; 2017 Dec; 108(12):503-507. PubMed ID: 29297899
[TBL] [Abstract][Full Text] [Related]
2. [Pembrolizumab for the treatment of melanoma: updates and perspectives.].
Chiarion Sileni V; Mandalà M; Queirolo P
Recenti Prog Med; 2017 Dec; 108(12):528-531. PubMed ID: 29297903
[TBL] [Abstract][Full Text] [Related]
3. Targeting complex, adaptive responses in melanoma therapy.
Cheng P; Levesque MP; Dummer R; Mangana J
Cancer Treat Rev; 2020 Jun; 86():101997. PubMed ID: 32179238
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab for the treatment of gastric cancer.
Kamath SD; Kalyan A; Benson AB
Expert Rev Anticancer Ther; 2018 Dec; 18(12):1177-1187. PubMed ID: 30280940
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy-based combinations: an update.
Fucà G; de Braud F; Di Nicola M
Curr Opin Oncol; 2018 Sep; 30(5):345-351. PubMed ID: 29994900
[TBL] [Abstract][Full Text] [Related]
6. Combination Immunotherapy Development in Melanoma.
Eggermont AMM; Crittenden M; Wargo J
Am Soc Clin Oncol Educ Book; 2018 May; 38():197-207. PubMed ID: 30231333
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum.
Salomon G; Maza A; Boulinguez S; Paul C; Lamant L; Tournier E; Mazereeuw-Hautier J; Meyer N
Br J Dermatol; 2018 May; 178(5):1199-1203. PubMed ID: 29274233
[TBL] [Abstract][Full Text] [Related]
8. Increase of lymphocytes and eosinophils, and decrease of neutrophils at an early stage of anti-PD-1 antibody treatment is a favorable sign for advanced malignant melanoma.
Ohashi H; Takeuchi S; Miyagaki T; Kadono T
Drug Discov Ther; 2020 Jul; 14(3):117-121. PubMed ID: 32595179
[TBL] [Abstract][Full Text] [Related]
9. Melanocytic lesion evolution patterns with targeted therapies and immunotherapies for advanced metastatic melanoma: An observational study.
Zhao CY; Hwang SJE; Wakade D; Carlos G; Anforth R; Fernández-Peñas P
Australas J Dermatol; 2017 Nov; 58(4):292-298. PubMed ID: 28707403
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series.
Finger PT; Pavlick AC
J Immunother Cancer; 2019 Mar; 7(1):83. PubMed ID: 30909967
[TBL] [Abstract][Full Text] [Related]
11. SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study.
Ribas A; Medina T; Kummar S; Amin A; Kalbasi A; Drabick JJ; Barve M; Daniels GA; Wong DJ; Schmidt EV; Candia AF; Coffman RL; Leung ACF; Janssen RS
Cancer Discov; 2018 Oct; 8(10):1250-1257. PubMed ID: 30154193
[TBL] [Abstract][Full Text] [Related]
12. Spotlight on pembrolizumab in the treatment of advanced melanoma.
Rajakulendran T; Adam DN
Drug Des Devel Ther; 2015; 9():2883-6. PubMed ID: 26082618
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma.
Sullivan RJ; Flaherty KT
Clin Cancer Res; 2015 Jul; 21(13):2892-7. PubMed ID: 25931451
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
[TBL] [Abstract][Full Text] [Related]
15. Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma.
Kirchberger MC; Hauschild A; Schuler G; Heinzerling L
Eur J Cancer; 2016 Sep; 65():182-4. PubMed ID: 27501507
[TBL] [Abstract][Full Text] [Related]
16. Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor.
Escandon J; Peacock S; Trabolsi A; Thomas DB; Layka A; Lutzky J
J Immunother Cancer; 2017; 5():3. PubMed ID: 28105370
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
Longoria TC; Tewari KS
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab in the treatment of advanced urothelial cancer.
Lundgren KT; Farina MS; Bellmunt J
Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016
[TBL] [Abstract][Full Text] [Related]
19. [Acceptability and effectiveness of immunotherapy in patients with melanoma].
Valnet-Rabier MB; Marcucci C; Limat S; Davani S; Aubin F; Nerich V
Therapie; 2019 Jun; 74(3):355-367. PubMed ID: 30193804
[TBL] [Abstract][Full Text] [Related]
20. [Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma].
Adam J; Tomasic G; Robert C
Ann Pathol; 2017 Feb; 37(1):55-60. PubMed ID: 28111041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]